The role of angiogenic, anti-angiogenic and vasoactive factors in pre-eclamptic African women: Early- versus late-onset pre-eclampsia

Cardiovascular Journal of Africa

Volumn 23, Issue 3, 2012, Pages 153-159

  Govender, Lucinda ^a   Mackraj, Irene ^a   Gathiram, Prem ^b   Moodley, Jack ^b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Angiogenic factors; Anti angiogenic factors; Placental AT1; PlGF; PlGF and sFlt 1 mRNAs; Pre eclampsia; sFlt 1; VEGF

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; MESSENGER RNA; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; NEGRO; ONSET AGE; PREECLAMPSIA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SOUTH AFRICA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMANS; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SOUTH AFRICA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84860322239     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: 10.5830/CVJA-2012-003     Document Type: Article

References (54)

1. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
2. Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res 2008; 75: 1-8. (Pubitemid 350266733)
3. Founds SA, Dorman JS, Conley YP. Microarray technology applied to the complex disorder of preeclampsia. J Obstet Gynecol Neonatal Nurs 2008; 37: 146-157.
4. Hawfield A, Freedman BI. Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection. Therapeut Adv Cardiovasc Dis 2009; 3: 65-73.
5. Roberts JM, Gammill H. Pre-eclampsia and cardiovascular disease in later life. Lancet 2005; 366: 961-962. (Pubitemid 41323014)
6. Pottecher J, Huet O, Degos V, Bonnet MP, Gaussem P, Duranteau J, et al. In vitro-induced endothelial oxidative stress and circulating markers of endothelial dysfunction in preeclampsia: an observational study. Hypertens Preg 2009; 28: 212-223.
7. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. New Engl J Med 2004; 350: 672-683. (Pubitemid 38364626)
8. McKeeman GC, Ardill JE, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004; 191: 1240-1246. (Pubitemid 39421577)
9. Foidart JM, Schaaps JP, Chantraine F, Munaut C, Lorquet S. Dysregulation of anti-angiogenic agents (sFlt-1, PIGF, and sEndoglin) in preeclampsia - a step forward but not the definitive answer. J Reproduc Immunol 2009; 82: 106-111.
10. Redman CW, Sargent IL. Placental stress and pre-eclampsia: a revised view. Placenta 2009; 30(Suppl A): S38-42.
11. Zhou CC, Ahmad S, Mi T, Xia L, Abbasi S, Hewett PW, et al. Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ Res 2007; 100: 88-95. (Pubitemid 46074969)
12. Shah DM. Role of the renin-angiotensin system in the pathogenesis of preeclampsia. Am J Physiol Renal Physiol 2005; 288: F614-625. (Pubitemid 40381727)
13. Dechend R, Gratze P, Wallukat G, Shagdarsuren E, Plehm R, Brasen JH, et al. Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension 2005; 45: 742-746. (Pubitemid 40418375)
14. Moodley J. Maternal deaths associated with hypertension in South Africa: lessons to learn from the Saving Mothers report, 2005-2007. Cardiovasc J Afr 2011; 22: 31-35.
15. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999; 96: 9212-9217. (Pubitemid 29374734)
16. Singh R, Mackraj I, Naidoo R, Gathiram P. Sanguinarine downregulates AT1a gene expression in a hypertensive rat model. J Cardiovasc Pharmacol 2006; 48: 14-21. (Pubitemid 44358889)
17. Eisenberg E, Levanon EY. Human housekeeping genes are compact. Trends Genet 2003; 19: 362-365. (Pubitemid 36794535)
18. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996; 6: 986-994. (Pubitemid 26388091)
19. Lu F, Longo M, Tamayo E, Maner W, Al-Hendy A, Anderson GD, et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol 2007; 196: 396 e1-7; discussion e7.
20. Malamitsi-Puchner A, Tziotis J, Protonotariou E, Sarandakou A, Creatsas G. Angiogenic factors in the perinatal period: diversity in biological functions reflected in their serum concentrations soon after birth. Ann NY Acad Sci 2000; 900: 169-173. (Pubitemid 30251466)
21. Semczuk-Sikora A, Krzyzanowski A, Kwiatek M, Semczuk M. [Maternal serum concentration of placental growth factor (PIGF) and endothelial growth factor (VEGF) in pregnancies complicated by preeclampsia]. Ginekologia Polska 2007; 78: 873-876.
22. Sun SG, Shen N, Zheng YH, Shang T. [Expression of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and sFlt-1 in preeclampsia placenta]. Zhonghua fu Chan Ke Za Zhi 2006; 41: 440-444.
23. Nagamatsu T, Fujii T, Kusumi M, Zou L, Yamashita T, Osuga Y, et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 2004; 145: 4838-4845.
24. Cirpan T, Akercan F, Terek MC, Kazandi M, Ozcakir HT, Giray G, et al. Evaluation of VEGF in placental bed biopsies from preeclamptic women by immunohistochemistry. Clin Exp Obstet Gynecol 2007; 34: 228-231.
25. Milovanov AP, Sidorova IS, Solonitsyn AN, Borovkova EI. [Immunohistochemical evaluation of the distribution of vascular endothelial growth factor in the placenta, placental bed in normal pregnancy and in women with preeclampsia]. Arkhiv Patologii 2008; 70: 12-15.
26. Cooper JC, Sharkey AM, Charnock-Jones DS, Palmer CR, Smith SK. VEGF mRNA levels in placentae from pregnancies complicated by preeclampsia. Br J Obstet Gynaecol 1996; 103: 1191-1196. (Pubitemid 26402883)
27. Akercan F, Cirpan T, Terek MC, Ozcakir HT, Giray G, Sagol S, et al. The immunohistochemical evaluation of VEGF in placenta biopsies of pregnancies complicated by preeclampsia. Arch Gynecol Obstet 2008; 277: 109-114. (Pubitemid 350308026)
28. Ranheim T, Staff AC, Henriksen T. VEGF mRNA is unaltered in decidual and placental tissues in preeclampsia at delivery. Acta Obstet Gynecol Scand 2001; 80: 93-98. (Pubitemid 32113460)
29. Sgambati E, Marini M, Zappoli Thyrion GD, Parretti E, Mello G, Orlando C, et al. VEGF expression in the placenta from pregnancies complicated by hypertensive disorders. Br J Obstet Gynaecol 2004; 111: 564-570. (Pubitemid 38746240)
30. Kulkarni AV, Mehendale SS, Yadav HR, Kilari AS, Taralekar VS, Joshi SR. Circulating angiogenic factors and their association with birth outcomes in preeclampsia. Hypertens Res 2010; 33: 561-567.
31. Dwyer BK, Krieg S, Balise R, Carroll IR, Chueh J, Nayak N, et al. Variable expression of soluble fms-like tyrosine kinase 1 in patients at high risk for preeclampsia. J Matern Fetal Neonatal Med 2010; 23: 705-711.
32. Tjoa ML, Levine RJ, Karumanchi SA. Angiogenic factors and preeclampsia. Front Biosci 2007; 12: 2395-2402.
33. Mittal P, Espinoza J, Hassan S, Kusanovic JP, Edwin SS, Nien JK, et al. Placental growth hormone is increased in the maternal and fetal serum of patients with preeclampsia. J Matern Fetal Neonatal Med 2007; 20: 651-659. (Pubitemid 47262701)
34. Robinson CJ, Johnson DD, Chang EY, Armstrong DM, Wang W. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 2006; 195: 255-259. (Pubitemid 43927517)
35. Wikstrom AK, Larsson A, Eriksson UJ, Nash P, Norden-Lindeberg S, Olovsson M. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol 2007; 109: 1368-1374. (Pubitemid 46869876)
36. Levine RJ, Qian C, Maynard SE, Yu KF, Epstein FH, Karumanchi SA. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol 2006; 194: 1034-1041.
37. Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005; 90: 4895-4903. (Pubitemid 41159388)
38. Maynard S, Epstein FH, Karumanchi SA. Preeclampsia and angiogenic imbalance. A Rev Med 2008; 59: 61-78. (Pubitemid 351287924)
39. Savvidou MD, Yu CK, Harland LC, Hingorani AD, Nicolaides KH. Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. Am J Obstet Gynecol 2006; 195: 1668-1673. (Pubitemid 44792614)
40. Karumanchi SA, Bdolah Y. Hypoxia and sFlt-1 in preeclampsia: the 'chicken-and-egg' question. Endocrinology 2004; 145: 4835-4837.
41. Karumanchi SA, Epstein FH. Placental ischemia and soluble fms-like tyrosine kinase 1: cause or consequence of preeclampsia? Kidney Int 2007; 71: 959-961. (Pubitemid 46742004)
42. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002; 160: 1405-1423. (Pubitemid 34411644)
43. Smith GC, Crossley JA, Aitken DA, Jenkins N, Lyall F, Cameron AD, et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol. 2007; 109: 1316-1324. (Pubitemid 46869870)
44. Smith GC, Wear H. The perinatal implications of angiogenic factors. Curr Opin Obstet Gynecol 2009; 21: 111-116.
45. Hirokoshi K, Maeshima Y, Kobayashi K, Matsuura E, Sugiyama H, Yamasaki Y, et al. Elevated serum sFlt-1/Ang-2 ratio in women with preeclampsia. Nephron 2007; 106: c43-50. (Pubitemid 46701512)
46. Zhou CC, Ahmad S, Mi T, Abbasi S, Xia L, Day MC, et al. Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension 2008; 51: 1010-1019. (Pubitemid 351398948)
47. Irani RA, Xia Y. The functional role of the renin-angiotensin system in pregnancy and preeclampsia. Placenta 2008; 29: 763-771.
48. Anguiano-Robledo L, Reyes-Melchor PA, Bobadilla-Lugo RA, Perez-Alvarez VM, Lopez-Sanchez P. Renal angiotensin-II receptors expression changes in a model of preeclampsia. Hypertens Preg 2007; 26: 151-161. (Pubitemid 46676551)
49. Hubel CA, Wallukat G, Wolf M, Herse F, Rajakumar A, Roberts JM, et al. Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension 2007; 49: 612-617.
50. Herse F, Verlohren S, Wenzel K, Pape J, Muller DN, Modrow S, et al. Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational agematched case study. Hypertension 2009; 53: 393-398.
51. Roberts CB, Rom L, Moodley J, Pegoraro RJ. Hypertension-related gene polymorphisms in pre-eclampsia, eclampsia and gestational hypertension in black South African women. J Hypertens 2004; 22: 945-948. (Pubitemid 38680469)
52. Wang Y, Gu Y, Lewis DF. Endothelial angiotensin II generation induced by placenta-derived factors from preeclampsia. Reproduct Sci 2008; 15: 932-938.
53. Doering TP, Haller NA, Montgomery MA, Freeman EJ, Hopkins MP. The role of AT1 angiotensin receptor activation in the pathogenesis of preeclampsia. Am J Obstet Gynecol 1998; 178: 1307-1312. (Pubitemid 28304635)
54. Smith RA, Baker PN. Risk factors, prevention and treatment of hypertension in pregnancy. Minerva Ginecolog 2005; 57: 379-388. (Pubitemid 41503744)